Market Access for BioPharmaceutical innovation is often described as confusing and full of risk for the innovative companies trying to bring new products to patients. However, in many cases, this is more perception than reality when we consider the risks and opportunities involved. In this tutorial, we help you to understand how companies can engage with HTA and regulatory organisations earlier than has usually been the case, and what are the potential benefits and risks of such an approach.